---
schema_version: "secwatch.filing_event.v1"
accession: "0000926617-26-000050"
form_type: "8-K/A"
ticker: "AWHL"
cik: "0000926617"
company_name: "Aspira Women's Health Inc."
filed_at: "2026-07-07T20:32:48+00:00"
generated_at: "2026-07-07T20:34:16.060651+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.45
calibrated_materiality_score: 0.45
confidence: "high"
source: SEC EDGAR
---

# Aspira Women's Health finalizes CEO Buhle separation: $200K severance, 64,583 options accelerated

## Summary
- Cash severance $200,000 (6 months base salary) payable in installments; prorated $4,615.38 on July 15 payroll if signed by June 29.
- Accelerated vesting of 64,583 stock options at $0.07/share, subject to Compensation Committee approval; all other unvested options forfeited.
- Shares from accelerated options subject to restrictions: 90-day lock-up, daily volume limit 2,500 shares, price floor $0.45, approved broker, advance notice.
- COBRA premium payments for 6 months; mutual release of claims; Buhle remains bound by confidentiality, non-solicitation, non-interference covenants.
- Separation Agreement effective after 7-day revocation period (expected July 6, 2026).

## SEC filing metadata
- accession: 0000926617-26-000050
- form_type: 8-K/A
- ticker: AWHL
- cik: 0000926617
- company_name: Aspira Women's Health Inc.
- filed_at: 2026-07-07T20:32:48+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.45
- calibrated_materiality_score: 0.45
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/926617/000092661726000050/0000926617-26-000050-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/926617/000092661726000050/awhl-20260617x8ka.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000926617-26-000050
- JSON: https://secwatch.observer/filing/0000926617-26-000050.json
- Plain text: https://secwatch.observer/filing/0000926617-26-000050.txt

## Key facts
- Executive change
  Michael Buhle departed as Chief Executive Officer at Aspira Women's Health Inc..
  - Action: ceased serving
  - Role: Chief Executive Officer
  source text: Michael Buhle ceased serving as the Company’s Chief Executive Officer effective June 17, 2026
  evidence_url: https://www.sec.gov/Archives/edgar/data/926617/000092661726000050/0000926617-26-000050-index.htm
- Executive change
  John (Jack) Fraser was appointed as Interim Chief Executive Officer at Aspira Women's Health Inc..
  - Action: appointed
  - Role: Interim Chief Executive Officer
  source text: appointed John (Jack) Fraser as Interim Chief Executive Officer
  evidence_url: https://www.sec.gov/Archives/edgar/data/926617/000092661726000050/0000926617-26-000050-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.